The phase 2a clinical trial (NCT04634253) evaluated the safety and efficacy of peresolimab in adult participants with moderate-to-severe RA who had an inadequate response to prior conventional, biologic or synthetic disease modifying antirheumatic drugs ( …
See Original Article

3 years ago, Anna (not her real name) was diagnosed with a neurological autoimmune disease in which her body attacks substances that are naturally found in the body, causing pain and vision loss. Before her diagnosis, Anna worked in software technology …
See Original Article